中华肿瘤杂志
中華腫瘤雜誌
중화종류잡지
CHINESE JOURNAL OF ONCOLOGY
2012年
4期
306-310
,共5页
侯芸%王华庆%付凯%刘贤明%张会来%钱正子%邱立华%李维%周世勇%李兰芳%郝希山
侯蕓%王華慶%付凱%劉賢明%張會來%錢正子%邱立華%李維%週世勇%李蘭芳%郝希山
후예%왕화경%부개%류현명%장회래%전정자%구립화%리유%주세용%리란방%학희산
淋巴瘤,非霍奇金%利妥昔单抗%复发%抗药性,肿瘤%治疗结果
淋巴瘤,非霍奇金%利妥昔單抗%複髮%抗藥性,腫瘤%治療結果
림파류,비곽기금%리타석단항%복발%항약성,종류%치료결과
Lymphoma,non-Hodgkin%Rituximab%Recurrence%Drug resistance,neoplasm%Treatment outcome
目的 评价利妥昔单抗联合NCE方案(长春瑞滨+顺铂+依托泊苷)治疗复发、耐药性B细胞非霍奇金淋巴瘤(NHL)的临床疗效和不良反应.方法 收集46例采用利妥昔单抗联合NCE方案治疗的复发、耐药性B细胞NHL患者的临床和随访资料,分析其近期疗效、远期生存状况和不良反应.结果 46例患者中位治疗4个周期.均可评价客观疗效,完全缓解率为52.17％,临床有效率为82.61％.中位随访69个月,1、3、5年生存率分别为74.8％,48.3％和40.1％,中位生存期为30.2个月(5～65个月),中位无进展生存期为10.9个月(2～31个月).主要不良反应为胃肠道反应、骨髓抑制、乏力、脱发、皮疹和发热.结论 利妥昔单抗联合NCE方案治疗复发、耐药性B细胞NHL的近期有效率和远期生存率较二线化疗方案高,且毒副作用可耐受,值得临床进一步推广使用.
目的 評價利妥昔單抗聯閤NCE方案(長春瑞濱+順鉑+依託泊苷)治療複髮、耐藥性B細胞非霍奇金淋巴瘤(NHL)的臨床療效和不良反應.方法 收集46例採用利妥昔單抗聯閤NCE方案治療的複髮、耐藥性B細胞NHL患者的臨床和隨訪資料,分析其近期療效、遠期生存狀況和不良反應.結果 46例患者中位治療4箇週期.均可評價客觀療效,完全緩解率為52.17％,臨床有效率為82.61％.中位隨訪69箇月,1、3、5年生存率分彆為74.8％,48.3％和40.1％,中位生存期為30.2箇月(5～65箇月),中位無進展生存期為10.9箇月(2～31箇月).主要不良反應為胃腸道反應、骨髓抑製、乏力、脫髮、皮疹和髮熱.結論 利妥昔單抗聯閤NCE方案治療複髮、耐藥性B細胞NHL的近期有效率和遠期生存率較二線化療方案高,且毒副作用可耐受,值得臨床進一步推廣使用.
목적 평개리타석단항연합NCE방안(장춘서빈+순박+의탁박감)치료복발、내약성B세포비곽기금림파류(NHL)적림상료효화불량반응.방법 수집46례채용리타석단항연합NCE방안치료적복발、내약성B세포NHL환자적림상화수방자료,분석기근기료효、원기생존상황화불량반응.결과 46례환자중위치료4개주기.균가평개객관료효,완전완해솔위52.17％,림상유효솔위82.61％.중위수방69개월,1、3、5년생존솔분별위74.8％,48.3％화40.1％,중위생존기위30.2개월(5～65개월),중위무진전생존기위10.9개월(2～31개월).주요불량반응위위장도반응、골수억제、핍력、탈발、피진화발열.결론 리타석단항연합NCE방안치료복발、내약성B세포NHL적근기유효솔화원기생존솔교이선화료방안고,차독부작용가내수,치득림상진일보추엄사용.
Objective The aim of this study was to analyze the efficacy and toxicity of RNCE regimen in the treatment of relapsed or refractory B cell non-Hodgkin's lymphoma (NHL).Methods From January 2000 to December 2005,46 patients with relapsed or refractory B cell NHL were treated by RNCE regimen with or without radiotherapy for the involved field.The clinical characteristics,response,toxicity and long-term survival results were analyzed retrospectively.Results A total of 46 patients were eligible.The complete response rate of second-line therapy was 52.17％ (24/46),and the overall response rate was 82.61％ (38/46).The median follow-up duration in this series was 69 months (range:6 to 102 months).The overall 1,3,5-year survival rate was 74.8％,48.3％,40.1％,respectively,with a median survival time of 30.2 months (5 to 65 months),and median progression free survival time of 10.9 months (2 to 31 months).The major toxicities were myelosuppression,GI toxicity,fatigue,fever and alopecia.Conclusion Our data show that RNCE regimen treatment is effective and well tolerated in patients with relapsed or refractory B cell non-Hodgkin's lymphoma.
